These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33099543)

  • 1. ctDNA in Neuroendocrine Carcinoma of Gastroenteropancreatic Origin or of Unknown Primary: The CIRCAN-NEC Pilot Study.
    Gerard L; Garcia J; Gauthier A; Lopez J; Durand A; Hervieu V; Lemelin A; Chardon L; Landel V; Gibert B; Lombard-Bohas C; Payen L; Walter T
    Neuroendocrinology; 2021; 111(10):951-964. PubMed ID: 33099543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
    Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
    Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms.
    Elvebakken H; Hjortland GO; Garresori H; Andresen PA; Janssen EAM; Vintermyr OK; Lothe IMB; Sorbye H
    J Neuroendocrinol; 2023 Apr; 35(4):e13256. PubMed ID: 37017614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF
    Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
    Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.
    Venizelos A; Elvebakken H; Perren A; Nikolaienko O; Deng W; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Krogh M; Sorbye H; Knappskog S
    Endocr Relat Cancer; 2021 Nov; 29(1):1-14. PubMed ID: 34647903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin.
    Hadoux J; Afchain P; Walter T; Tougeron D; Hautefeuille V; Monterymard C; Lorgis V; Thuillier F; Baudin E; Scoazec JY; Lepage C; Desgrippes R
    Dig Liver Dis; 2021 Jul; 53(7):824-829. PubMed ID: 33994125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms.
    Brandi G; Paragona M; Campana D; Brighi N; Bondi A; Pantaleo MA; Corbelli J; Barbera MA; Biasco G
    J Chemother; 2018 Feb; 30(1):53-58. PubMed ID: 28641483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
    Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
    Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular features of gastroenteropancreatic neuroendocrine carcinoma: A comparative analysis with lung neuroendocrine carcinoma and digestive adenocarcinomas.
    Zhang J; Chen H; Zhang J; Wang S; Guan Y; Gu W; Li J; Zhang X; Li J; Wang X; Lu Z; Zhou J; Peng Z; Sun Y; Shao Y; Shen L; Zhuo M; Lu M
    Chin J Cancer Res; 2024 Feb; 36(1):90-102. PubMed ID: 38455367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study.
    Huang L; Lv Y; Guan S; Yan H; Han L; Wang Z; Han Q; Dai G; Shi Y
    J Transl Med; 2024 Feb; 22(1):184. PubMed ID: 38378604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms.
    Elvebakken H; Venizelos A; Perren A; Couvelard A; Lothe IMB; Hjortland GO; Myklebust TÅ; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Vestermark LW; Knappskog S; Sorbye H
    Br J Cancer; 2024 Sep; 131(4):676-684. PubMed ID: 38909137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913).
    Riesco-Martinez MC; Capdevila J; Alonso V; Jimenez-Fonseca P; Teule A; Grande E; Sevilla I; Benavent M; Alonso-Gordoa T; Custodio A; Anton-Pascual B; Hernando J; Polo E; Castillo-Trujillo OA; Lamas-Paz A; Teijo A; Rodriguez-Gil Y; Soldevilla B; Garcia-Carbonero R
    Nat Commun; 2024 Aug; 15(1):6753. PubMed ID: 39117670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.
    Galleberg RB; Knigge U; Tiensuu Janson E; Vestermark LW; Haugvik SP; Ladekarl M; Langer SW; Grønbæk H; Österlund P; Hjortland GO; Assmus J; Tang L; Perren A; Sorbye H
    Eur J Surg Oncol; 2017 Sep; 43(9):1682-1689. PubMed ID: 28522174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
    Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
    Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.
    Walter T; Malka D; Hentic O; Lombard-Bohas C; Le Malicot K; Smith D; Ferru A; Assenat E; Cadiot G; Lievre A; Kurtz JE; Dahan L; Dubreuil O; Hautefeuille V; Lepere C; Gangloff A; Elhajbi F; Coriat R; Roquin G; Bouarioua N; Granger V; Scoazec JY; Lepage C
    Dig Liver Dis; 2018 Feb; 50(2):195-198. PubMed ID: 29258812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort.
    Lithgow K; Venkataraman H; Hughes S; Shah H; Kemp-Blake J; Vickrage S; Smith S; Humphries S; Elshafie M; Taniere P; Diaz-Cano S; Dasari BVM; Almond M; Ford S; Ayuk J; Shetty S; Shah T; Geh I
    Sci Rep; 2021 Sep; 11(1):17947. PubMed ID: 34504148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
    Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
    Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
    Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
    J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Subset of Large Cell Neuroendocrine Carcinomas in the Gastroenteropancreatic Tract May Evolve from Pre-existing Well-Differentiated Neuroendocrine Tumors.
    Pelosi G; Bianchi F; Dama E; Metovic J; Barella M; Sonzogni A; Albini A; Papotti M; Gong Y; Vijayvergia N
    Endocr Pathol; 2021 Sep; 32(3):396-407. PubMed ID: 33433886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma.
    Thomas KEH; Voros BA; Boudreaux JP; Thiagarajan R; Woltering EA; Ramirez RA
    Oncologist; 2019 Aug; 24(8):1076-1088. PubMed ID: 30635447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.